An observational trial of Zygel in Developmental and Epileptic Encephalopathies (DEE)
Latest Information Update: 15 Aug 2021
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Sponsors Zynerba Pharmaceuticals
- 09 Aug 2021 According to the Zynerba Pharmaceuticals media release, due to the heterogeneity of patients who fall under the DEE umbrella, the FDA suggested the company pursue individual syndromes rather than considering DEE as a single disorder or condition
- 12 Mar 2021 New trial record
- 10 Mar 2021 According to the Zynerba Pharmaceuticals media release, this study will be conducted by the end of 2021.